Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use

This study has been completed.
Sponsor:
Collaborator:
Otsuka Pharmaceutical Co., Ltd.
Information provided by:
Otsuka Pharmaceutical Development & Commercialization, Inc.
ClinicalTrials.gov Identifier:
NCT01141400
First received: June 9, 2010
Last updated: November 7, 2013
Last verified: November 2010

June 9, 2010
November 7, 2013
June 2009
October 2010   (final data collection date for primary outcome measure)
The primary outcome is any use of adjunctive treatment (combined and by class) and the time to initiation of adjunctive treatment (combined and by class). [ Time Frame: 16 months ] [ Designated as safety issue: No ]
16 months of medical and prescription drug coverage after the initial antidepressant prescription claim
Same as current
Complete list of historical versions of study NCT01141400 on ClinicalTrials.gov Archive Site
sensitivity to cost-sharing will be examined as a function of treatment resistance [ Time Frame: 16 months ] [ Designated as safety issue: No ]
16 months of medical and prescription drug coverage after the initial antidepressant prescription claim
Same as current
Not Provided
Not Provided
 
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use
The Effect of Patient Cost-Sharing on Antidepressant and Adjunctive Therapy Use

The primary objective of this study is to measure the effects of patient cost-sharing on the initiation of adjunctive treatment and subsequent healthcare utilization and expenditures among a population of commercially insured adults on antidepressant therapy.

Not Provided
Observational
Observational Model: Cohort
Time Perspective: Retrospective
Not Provided
Not Provided
Non-Probability Sample

Patients will be selected from the MarketScan Commercial Database between January 1, 2004 and September 30, 2008 (the last month of data available)

Depressive Disorder, Major
Not Provided
depression & initial prescription for an antidepressant
A sample of adults with a diagnosis of depression and an initial prescription fill for an antidepressant
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
48865
October 2010
October 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Adult patients (aged 18-64) will be selected from the MarketScan Commercial Database between January 1, 2004, and September 30, 2008, if they have at least two medical claims with a diagnosis of depression and at least one prescription fill for an antidepressant medication.

Exclusion Criteria:

  • Patients who have any claim with a diagnosis of dementia, schizophrenia, delusional disorder, psychoses, pervasive development disorder, mental retardation, cerebral degenerations, Parkinson's disease, senility, manic depression, bipolar disorder, or major depressive disorder with psychotic symptoms.
Both
18 Years to 64 Years
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT01141400
CN138-587
No
Study Director, Bristol-Myers Squibb
Otsuka Pharmaceutical Development & Commercialization, Inc.
Otsuka Pharmaceutical Co., Ltd.
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
Otsuka Pharmaceutical Development & Commercialization, Inc.
November 2010

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP